Embecta Corp. Files 2024 Annual Report
Ticker: EMBC · Form: 10-K · Filed: Dec 11, 2024 · CIK: 1872789
| Field | Detail |
|---|---|
| Company | Embecta CORP. (EMBC) |
| Form Type | 10-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, financials
TL;DR
Embecta filed its 2024 10-K. Check financials.
AI Summary
Embecta Corp. filed its 10-K for the fiscal year ending September 30, 2024. The company, formerly known as Berra Newco, Inc. until July 14, 2021, is a manufacturer of surgical and medical instruments. Its principal executive offices are located at 1209 Orange Street, Wilmington, DE.
Why It Matters
This filing provides a comprehensive overview of Embecta Corp.'s financial performance and business operations for the fiscal year 2024, crucial for investors and stakeholders to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a standard annual financial filing with no immediate red flags or urgent disclosures.
Key Players & Entities
- Embecta Corp. (company) — Filer of the 10-K
- Berra Newco, Inc. (company) — Former name of Embecta Corp.
- 20240930 (date) — Fiscal year end
- 20210714 (date) — Date of former company name change
- 1209 Orange Street, Wilmington, DE 19801 (address) — Principal business address
FAQ
What is Embecta Corp.'s primary business?
Embecta Corp. is engaged in the manufacturing of surgical and medical instruments and apparatus, as indicated by its SIC code 3841.
When did Embecta Corp. change its name from Berra Newco, Inc.?
Embecta Corp. changed its name from Berra Newco, Inc. on July 14, 2021.
What is the fiscal year end for Embecta Corp.?
Embecta Corp.'s fiscal year ends on September 30.
Where are Embecta Corp.'s principal executive offices located?
Embecta Corp.'s principal executive offices are located at 1209 Orange Street, Wilmington, DE 19801.
What is the SEC file number for Embecta Corp.'s 10-K filing?
The SEC file number for Embecta Corp.'s 10-K filing is 001-41186.
Filing Stats: 4,480 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2024-12-11 16:52:35
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share EMBC The Nasdaq Stock Market
Filing Documents
- embc-20240930.htm (10-K) — 1732KB
- q4202410kexhibit1014.htm (EX-10.14) — 44KB
- q4202410kexhibit19.htm (EX-19) — 47KB
- q4202410kexhibit211.htm (EX-21.1) — 34KB
- q4202410kexhibit231.htm (EX-23.1) — 2KB
- q4202410kexhibit311.htm (EX-31.1) — 10KB
- q4202410kexhibit312.htm (EX-31.2) — 10KB
- q4202410kexhibit321.htm (EX-32.1) — 4KB
- q4202410kexhibit322.htm (EX-32.2) — 4KB
- embc-20240930_g1.jpg (GRAPHIC) — 33KB
- embc-20240930_g2.jpg (GRAPHIC) — 305KB
- 0001872789-24-000037.txt ( ) — 11088KB
- embc-20240930.xsd (EX-101.SCH) — 75KB
- embc-20240930_cal.xml (EX-101.CAL) — 129KB
- embc-20240930_def.xml (EX-101.DEF) — 298KB
- embc-20240930_lab.xml (EX-101.LAB) — 906KB
- embc-20240930_pre.xml (EX-101.PRE) — 634KB
- embc-20240930_htm.xml (XML) — 1493KB
Business
Item 1. Business. 1
Risk Factors
Item 1A. Risk Factors. 5
Unresolved Staff Comments
Item 1B. Unresolved Staff Comments. 30
Cybersecurity
Item 1C. Cybersecurity 30
Properties
Item 2. Properties. 31
Legal Proceedings
Item 3. Legal Proceedings. 31
Mine Safety Disclosures
Item 4. Mine Safety Disclosures. 31 Part II.
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 32
[ Reserved ]
Item 6. [ Reserved ]. 33
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. 33
Quantitative and Qualitative Disclosures About Market Risk
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 44
Financial Statements and Supplementary Data
Item 8. Financial Statements and Supplementary Data 45
Changes in and Disagreements With Accountants on Accounting and Financial Disclosures
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures. 82
Controls and Procedures
Item 9A. Controls and Procedures. 82
Other Information
Item 9B. Other Information.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. Part III. 85
Directors, Executive Officers and Corporate Governance
Item 10. Directors, Executive Officers and Corporate Governance. 85
Executive Compensation
Item 11. Executive Compensation. 85
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 85
Certain Relationships and Related Transactions, and Director Independence
Item 13. Certain Relationships and Related Transactions, and Director Independence. 85
Principal Accountant Fees and Services
Item 14. Principal Accountant Fees and Services. 85 Part IV. 86
Exhibits and Financial Statement Schedules
Item 15. Exhibits and Financial Statement Schedules. 86
Form 10-K Summary
Item 16. Form 10-K Summary. 88
Signatures
Signatures 89 i PART I.
Business
Item 1. Business. General Embecta Corp. (also referred to herein as "Embecta") was formed through a spin-off of the diabetes care business (the "Separation") from Becton, Dickinson and Company ("BD"). All references in this Form 10-K to "Embecta", "the Company", "we", "our" or "us" refer to Embecta Corp., a Delaware corporation, and its subsidiaries, unless otherwise indicated by the context. On April 1, 2022 (the "Separation Date"), Embecta and BD entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement"). Pursuant to the Separation and Distribution Agreement, BD agreed to spin off its diabetes care business ("Diabetes Care Business") into Embecta, a new, publicly traded company. We are a leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. Building on our 100-year centennial, we believe that our products have become one of the most widely recognized and respected brands in diabetes management throughout the world. We estimate that our products are used by more than 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes. We have a broad portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Our conventional pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. We also sell safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Our conventional and safety pen needles are compatible and frequently used with widely available pen injectors in the market today. In addition to pen needles, we sell sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. We